FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4 | BMC Cancer | Full Text

FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4 | BMC Cancer | Full Text

Featured article: Pre-clinical activity of novel systemic anti-cancer therapeutic peptides

Tracy Robson and colleagues demonstrate the pre-clinical activity of FKBPL-based anti-cancer therapeutic peptides, AD-01 and ALM201, in the metastatic setting, which can specifically target tamoxifen or endocrine therapy-resistant cancer stem cells